{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:31:40Z","timestamp":1770485500611,"version":"3.49.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,7,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Autologous stem cell transplantation (ASCT) has long been considered frontline therapy for newly diagnosed myeloma patients. This Spotlight examines the role of ASCT in the era of novel drugs and argues that ASCT should continue to be considered for eligible patients. A combination of novel drugs with ASCT in a sequential treatment approach can attain long-term survival and perhaps cure a subset of patients. ASCT will likely remain an important platform to develop curative strategies in the foreseeable future.<\/jats:p>","DOI":"10.1182\/blood-2014-03-561985","type":"journal-article","created":{"date-parts":[[2014,6,3]],"date-time":"2014-06-03T22:23:09Z","timestamp":1401834189000},"page":"328-333","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["The future of autologous stem cell transplantation in myeloma"],"prefix":"10.1182","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-1282","authenticated-orcid":false,"given":"Frits","family":"van Rhee","sequence":"first","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"27","key":"2019111823001101600_B1","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1182\/blood-2009-07-204651","article-title":"How I treat multiple myeloma in younger patients.","volume":"114","author":"Stewart","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111823001101600_B2","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","article-title":"Approach to the treatment of multiple myeloma: a clash of philosophies.","volume":"118","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111823001101600_B3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2006.06271.x","article-title":"Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.","volume":"135","author":"Barlogie","year":"2006","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111823001101600_B4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","article-title":"Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.","volume":"118","author":"Martinez-Lopez","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111823001101600_B5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","article-title":"Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma.","volume":"92","author":"van de Velde","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"2019111823001101600_B6","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/bmt.2009.176","article-title":"CR represents an early index of potential long survival in multiple myeloma.","volume":"45","author":"Wang","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111823001101600_B7","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma.","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"22","key":"2019111823001101600_B8","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111823001101600_B9","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study.","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"issue":"9758","key":"2019111823001101600_B10","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"2019111823001101600_B11","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial.","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111823001101600_B12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/leu.2012.160","article-title":"Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?","volume":"27","author":"Usmani","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"2019111823001101600_B13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.193.193","article-title":"Metaphase cytogenetic abnormality (CA) subtypes in multiple myeloma (MM) treated with front line total therapy (TT) protocols TT1, TT2, TT3, TT4 and TT5 [abstract].","volume":"120","author":"van Rhee","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111823001101600_B14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2089.2089","article-title":"Maintenance therapy with lenalidomide significantly improved survival of young newly diagnosed multiple myeloma patients [abstract].","volume":"122","author":"Gay","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111823001101600_B15","article-title":"A phase III study of ASCT vs cyclophosphamide-lenalidomide-dexamethasone and lenalidomide-prednisone maintenance vs lenalidomide alone in newly diagnosed myeloma patients [abstract].","volume":"122","author":"Palumbo","year":"2013","journal-title":"Blood"},{"issue":"30","key":"2019111823001101600_B16","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111823001101600_B17","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.","volume":"119","author":"Neben","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2019111823001101600_B18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7","key":"2019111823001101600_B19","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood-2005-10-4084","article-title":"Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.","volume":"107","author":"Barlogie","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2019111823001101600_B20","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.","volume":"28","author":"Ladetto","year":"2010","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111823001101600_B21","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1182\/blood-2012-11-464503","article-title":"Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.","volume":"121","author":"Mellqvist","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111823001101600_B22","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","article-title":"A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.","volume":"121","author":"Stewart","year":"2013","journal-title":"Blood"},{"issue":"20","key":"2019111823001101600_B23","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111823001101600_B24","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111823001101600_B25","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma.","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111823001101600_B26","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"issue":"10","key":"2019111823001101600_B27","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111823001101600_B28","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood"},{"issue":"121","key":"2019111823001101600_B29","article-title":"Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in the ECOG E4A03 randomized clinical trial [abstract].","volume":"116","author":"Siegel","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111823001101600_B30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111823001101600_B31","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/cncr.26422","article-title":"Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma.","volume":"118","author":"Kumar","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"2019111823001101600_B32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2141.2006.06441.x","article-title":"Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.","volume":"136","author":"Pineda-Roman","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111823001101600_B33","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"issue":"23","key":"2019111823001101600_B34","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1158\/1078-0432.CCR-07-0527","article-title":"Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.","volume":"13","author":"Haessler","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111823001101600_B35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cncr.23546","article-title":"Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma.","volume":"113","author":"Barlogie","year":"2008","journal-title":"Cancer"},{"issue":"9","key":"2019111823001101600_B36","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.","volume":"25","author":"Walker","year":"2007","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111823001101600_B37","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111823001101600_B38","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111823001101600_B39","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111823001101600_B40","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.538.538","article-title":"Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of mrd negativity in newly diagnosed multiple myeloma (MM) patients [abstract].","volume":"122","author":"Korde","year":"2013","journal-title":"Blood"},{"issue":"18","key":"2019111823001101600_B41","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2009.26.4465","article-title":"Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.","volume":"28","author":"Barlogie","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7339","key":"2019111823001101600_B42","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma.","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"5","key":"2019111823001101600_B43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma.","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"2019111823001101600_B44","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.2011.39.9436","article-title":"Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.","volume":"30","author":"Griggs","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111823001101600_B45","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bmt.1705471","article-title":"Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.","volume":"38","author":"Grazziutti","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"2019111823001101600_B46","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","article-title":"Bortezomib-induced \u201cBRCAness\u201d sensitizes multiple myeloma cells to PARP inhibitors.","volume":"118","author":"Neri","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111823001101600_B47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","article-title":"Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).","volume":"115","author":"Roussel","year":"2010","journal-title":"Blood"},{"key":"2019111823001101600_B48","article-title":"Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma [published online ahead of print January 13, 2014].","author":"Melchor","journal-title":"Leukemia"},{"issue":"11","key":"2019111823001101600_B49","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma.","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111823001101600_B50","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","article-title":"Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.","volume":"121","author":"Gahrton","year":"2013","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/3\/328\/1464885\/328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/3\/328\/1464885\/328.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T23:00:31Z","timestamp":1574118031000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/124\/3\/328\/33128\/The-future-of-autologous-stem-cell-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,17]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,7,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-03-561985","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,17]]}}}